BRAF and colorectal carcinoma: CMS2 is an over-activated epithelial growth factor pathway with higher expression of EGFR and the EGFR-ligands amphiregulin and epiregulin, that are correlated to an increased response to EGFR inhibitor therapy in RAS/BRAF wt CRC (17).